Help find new options for Celiac Disease

Last updated: May 25, 2023
Sponsor: Chugai Pharmaceuticals
Overall Status: Active - Recruiting

Phase

1

Condition

Celiac Disease

Treatment

N/A

Clinical Study ID

TX312835
DQB101US
  • Ages 18-70
  • All Genders

Study Summary

This study will explore whether the study medication is safe for adults with celiac disease. The study medication is an antibody (a protein found in the immune system). It is designed to help protect the small intestine of someone with celiac disease. You may be able to participate if you have celiac disease and are 18-70 years old. Other study requirements apply.

Eligibility Criteria

Inclusion

Inclusion Criteria:

*

Exclusion

Exclusion Criteria:

*

Study Design

Study Start date:
June 03, 2023
Estimated Completion Date:

Study Description

Study participants receive at no cost:

  • 3 in 4 chances of receiving the study medication (some participants will receive placebo, which has no active ingredients)
  • Study support and monitoring by a healthcare team
  • More information about the genetic factors in your celiac disease
  • The opportunity to help advance celiac disease research

Connect with a study center

  • North Carolina Clinical Research

    Raleigh, North Carolina 27607
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.